Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
Satellos Bioscience reported positive six-month interim data from the Phase 2 TRAILHEAD study of SAT-3247 in adults with Duchenne muscular dystrophy. Results in four participants showed a mean 3.7% improvement in muscle fat fraction and a 34% increase in maximum upper limb effort, alongside a 38% reduction in the muscle damage biomarker CK.
Key figures
- Drug Name
- SAT-3247
- Phase Of Trial
- Phase 2
- Participants
- 4
- Ck reduction pct
- 38
- Te99c improvement pct
- approximately 34%
- Pedsql improvement pts
- 6.94
- Fat fraction improvement pct
- 3.7
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.